Table 3.
Efficacy of Intercalating and Maintenance Use of Gefitinib plus Chemotherapy vs. Chemotherapy alone for NSCLC Patients Stratified by EGFR Mutational Status (n = 30).
| Sensitive EGFR mutations | Wildtype EGFR | |||
|---|---|---|---|---|
| Arm A | Arm B | Arm A | Arm B | |
| No. of patients | 7 | 10 | 9 | 4 |
| ORR | 2 | 0 | 0 | 0 |
| Median PFS (months) | 12.1 (95% CI, 4.0–18.7) | 3.9 (95% CI, 2.0–4.6) | 3.4 (95% CI, 1.7–9.3) | 5.0 (95% CI, 2.0–7.8) |
| Median OS (months) | 32.0 (95% CI, 10.9–35.5) | 21.1 (95% CI, 11.1–32.3) | 16.9 (NA) | NA |
NOTE: Objective response rate (ORR) = Complete response plus partial response; Arm A: gemcitabine + carboplatin + gefitinib; Arm B: gemcitabine + carboplatin. Abbreviation: HR = hazards ratio; OS = overall survival; PFS = progression-free survival.